Drugs / fluticasone propionate/salmeterol
fluticasone propionate/salmeterol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00864812 | Mar 2009 → Mar 2010 | chronic obstructive pulmonary disease | The Korean Academy of Tuberculosis and Respiratory Diseases | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2017-12-21 | GlaxoSmithKline | Regulatory FDA approves US label update on ICS/LABA combinations in asthma, based on review of safety data gsk.com ↗
These labelling updates were approved on December 20th 2017, after a review of safety data from 4 randomized controlled safety trials submitted by three companies, including GSK. |
| 2016-03-06 | GlaxoSmithKline | Results NEJM publishes results of GSK’s long-term LABA safety study of Advair ® Diskus® in adults and adolescents with asthma gsk.com ↗
This was assessed by the composite endpoint of serious asthma-related events (deaths, intubations or hospitalisations) and showed that Advair had a safety profile comparable to FP, including no asthma-related deaths in either arm. |
| 2015-05-19 | GlaxoSmithKline | Results GSK presents data at ATS on the role of blood eosinophil levels as a potential biomarker in the treatment of COPD gsk.com ↗
GSK today presented two abstracts at the American Thoracic Society (ATS) meeting that provide data on the role of blood eosinophils as a potential biomarker to determine responsiveness to treatment with an inhaled corticosteroid (ICS) in patients with COPD. |
| 2014-03-14 | GlaxoSmithKline | Results GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS® and ADVAIR® DISKUS® in patients with COPD gsk.com ↗
We are pleased to announce the results from these positive studies, which provide physicians with further data regarding UMEC/VI as a treatment option for appropriate patients with COPD. |
| 2012-01-09 | GlaxoSmithKline | Results GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily Relovair™* in COPD and asthma gsk.com ↗
There was no statistical difference between FF/VI and FP/SAL. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-12-21 | GlaxoSmithKline | FDA approves US label update on ICS/LABA combinations in asthma, based on review of safety data gsk.com ↗ |
| 2016-03-06 | GlaxoSmithKline | NEJM publishes results of GSK’s long-term LABA safety study of Advair ® Diskus® in adults and adolescents with asthma gsk.com ↗ |
| 2015-05-19 | GlaxoSmithKline | GSK presents data at ATS on the role of blood eosinophil levels as a potential biomarker in the treatment of COPD gsk.com ↗ |
| 2014-03-14 | GlaxoSmithKline | GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS® and ADVAIR® DISKUS® in patients with COPD gsk.com ↗ |
| 2012-01-09 | GlaxoSmithKline | GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily Relovair™* in COPD and asthma gsk.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fluticasone propionate/salmeterol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00864812 ↗ |
| Known as | fluticasone propionate/salmeterol (FSC): Seretide | “fluticasone propionate/salmeterol (FSC): Seretide” NCT00864812 ↗ |
| Known as | FSC | “tiotropium with fluticasone propionate/salmeterol (FSC)” NCT00864812 ↗ |